1 Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, USA 2 Division of Biostatistics, Mayo Clinic and Foundation, Rochester, MN, USA Correspondence to: Dr E V ...
2 Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan 3 Department of Internal Medicine, GI Unit, Massachusetts General Hospital, Boston, Massachusetts, USA 4 ...
Background Clinicians use fibrosis in a liver biopsy to predict clinical outcomes of chronic liver disease. The performance of non-invasive tests has been evaluated against histological assessment of ...
Correspondence to Scott L Friedman, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, 1425 Madison Ave., Room 11-70C, Box 1123, New York, NY 10029-6574, USA; ...
Correspondence to Professor Shiv Kumar Sarin, Hepatology, Institute of Liver and Biliary Sciences, New Delhi, Delhi 110070, India; shivsarin{at}gmail.com Objectives Beta-blockers and endoscopic ...
Correspondence to Mr Amyn Haji, King’s Institute of Therapeutic Endoscopy, King’s College Hospital NHS Foundation Trust, London, SE5 9RS, UK; amynhaji{at}me.com If you wish to reuse any or all of this ...
BACKGROUND/AIMS Intestinal metaplasia (IM) is a common finding at the oesophagogastric junction, but the aetiopathogenesis of the different IM subtypes—that is, incomplete IM (specialised columnar ...
Correspondence to Dr Michael Blaise Cook, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, 9609 Medical Center Drive, Rm 7-E106, MSC 9774, Bethesda, MD 20892-9774, ...
BACKGROUND Crohn's disease is a heterogeneous disorder with both a genetic and environmental aetiology. Clinical classifications of the disease, such as the newly proposed Vienna classification, may ...
After innumerable negative or inconclusive studies to find a pharmacological prophylactic for post-ERCP pancreatitis (PEP), two randomised trials in the USA1 and China2 ushered a new era of ...
Background With population ageing, elderly patients account for a growing proportion of hepatic surgery recipients. Hepatic ischaemia-reperfusion injury (HIRI) is a major cause of postoperative liver ...
Background The combination of atezolizumab and bevacizumab (ATZ/BVZ) therapy has significantly advanced therapeutic approaches for hepatocellular carcinoma (HCC). However, less than 30% of patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback